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Immunologic Classification of Lymphoma 
and Lymphoid Leukemia 
K. A. Foon, R. P. Gale 
SUMMARY. Important insights into lymphocyte diiferentiation and the cellular origins of lymphoma 
and lymphoid leukemia have been gained through the use of monoclonal antibodii that define cell 
surface antigens and molecular probes that identify immunoglohulin and T cell receptor genes. Results 
of these studies have been combined with markers such as surface membrane and cytoplasmic 
immunoglobulin on B lymphocytes, sheep erythrocyte receptors on T lymphocytes, and cytochemical 
stains. Utilising all of the above markers, it is now clear that acute lymphoblastic leukemia (ALL) is 
heterogeneous. Furthermore, monoclonal antibodies that identify B cells such as the anti-B1 and 
anti-B4 antibodies in combination with studies of immunoglobulin gene rearrangement have 
demonstrated that virtually all cases of non-T-ALL involve B lymphocytes. At least six distinct 
subgroups of non-T-ALL can now be identified. T-ALL is subdivided by the anti-Leu-9, anti-Leu-1, 
and additional antibodies that separate T lymphocyte subsets into three primary subgroups. 
Monocloaal antibodies are also useful in the subclassiftcation of non-Hodgkin’s lymphoma, and 
certain distinct markers can be correlated with morphologic classification. 
Recent advances in immunology have led to impor- 
tant insights into lymphocyte differentiation and the 
cellular origin of lymphoma and lymphoid leukemia. 
It is now possible to precisely define stages of human 
lymphocyte differentiation utilising highly specific 
monoclonal antibodies that define cell surface anti- 
gens and molecular probes that identify rearrange- 
ment of immunoglobulin and T cell receptor genes. 
These can be combined with more traditional cell 
markers such as surface membrane (SmIg) and cyto- 
plasmic immunoglobulin (CIg) on B lymphocytes, 
sheep erythrocyte receptors on T lymphocytes, and 
cytochemical stains. In this review, we summarise ad- 
vances in the classification of lymphoma and the lym- 
phoid leukemias and their importance in our 
understanding normal lymphoid differentiation and 
therapeutic implications. 
K. A. Fuon, Division of Hematology and Oncology, Department of 
Internal Medicine, University of Michigan, Ann Arbor, MI and 
R P Gale, the Division of Hematology and Oncology, Department 
of Internal Medicine, and the Transplantation Biology Unit, 
University of California. Los Angeles. 
Cell Markers 
B Lymphocytes 
B lymphocytes are usually identified by the presence 
of SmIg. Progenitors of B lymphocytes, commonly 
referred to as ‘pre-B cells’ are present in fetal liver and 
normal bone marrow; the cells display cytoplasmic 
p-heavy chain (Cp) but lack intracytoplasmic light 
chain and SmIg. B and pre-B lymphocytes may also 
have receptors for the third component of comple- 
ment (C’3) and for the Fc portion of IgG. Fc and 
c’3 receptors are not specific for the B cell lineage 
and are found in other cells such as monocytes and 
some nonhematopoietic cells. Similarly, 
histocompatibility-related antigens (Ia or HLA-DR) 
are also found on the surface of B cells, but are not 
unique to them. l-4 Plasma cells are the most mature B 
lymphocytes; they lack detectable SmIg but have CIg. 
Unlike the CIg found in pre-B lymphocytes, CIg in 
plasma cells includes both heavy and light chains. 
A number of heteroantisera and, more recently, 
monoclonal antibodies that identify B cell-associated 
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Table 1 Monoclonal Antibodies Reactive with Human B Lymphocytes 
Antibody (subclass) Pattern of Reactivity 
Molecular Weight 
of Antigen (kd) 
Cluster 
Designation Reference 
anti-B1 B lymphocytes, malignant B cells 35 CD20 8 
anti-B2 B lymphocytes, malignant B cells (receptor for 
Epstein-Barr virus and C3d) 140 CD21 9, 10 
anti-B4 B lymphocytes, malignant B cells 40 CD19 7 
BA-I B lymphocytes, granulocytes, malignant B cells 45, 55,65 CD24 II,12 
FMCI B lymphocytes, malignant B cells NR NA 13 
FMC7 < 50% B lymphocytes, some malignant B cells NR NA 14 
J5, BA-3 Granulocytes, most non-T-ALL, Burkitt’s 
lymphoma, follicular lymphoma, some 
lymphoblastic lymphoma and T-ALL 100 CD10 4-6 
anti-PCA- 1 and anti- Plasma cells, malignant plasma cells, weakly on NR NA 15 
PCA 2 monocytes and granulocytes 
anti-PC-l Plasma cells, malignant plasma cells 28 NA 16 
NR, not reported; NA, not applicable. 
The anti-B series, anti PC-l, and anti PCA-1 are available through Coulter Immunology, Hialeah, Florida; BA-1 through Hybritech Inc., 
San Diego, California; and the OKB series through Ortho System, Inc., Raritan, NJ. 
Table 2 Monoclonal Antibodies Reactive with Human T Lymphocytes 
Molecular Weight Cluster 
Antibody Pattern of Reactivity of Antigen (kd) Designation Reference 
0KT6, NAl/34, anti-Leu-6 Thymocytes 45 CD1 21 
OKTl 1, anti-T1 1, anti-Leu-5 Pan-T lymphocyte (E receptor) 4&50 CD2 23,24 
OKT3, anti-T3, anti-Leu-4 Pan-T lymphocyte (mitogenic) 20,20,25 CD3 21 
OKT4, anti-T4, anti-Leu-3 T helper/inducer 55 CD4 21,22 
OKTI, anti-Tl, anti-Leu-I, TlOl Pan-T lymphocyte, pan-thymocyte 65 CD5 21,25,26 
3A1, anti-Leu-9 (4H9), WTI Pan-T lymphocyte, pan-thymocyte 40 CD7 27-29 
OKT5,OKT8, anti-T& anti-Leu-2 T cytotoxic/suppressor 3243 CD8 22 
Anti-Tat Interieukin-2 receptor 55 CD25 31 
Anti-TQI Subset of T inducer cells NR NA 31 
OKT9,5E9 Thymocytes, lymphoblasts, monocytes 90 NA 20,21 
(anti-transferrin) 
OKTlO Thymocytes 45 NA 20 
NR, not reported; NA, not applicable. 
The OKT series of antibodies are available through Ortho Systems, Inc., Raritan, NJ; Leu series through Becton-Dickinson Co., 
Mountainview, California; anti-T through Coulter Immunology, Hialeah, Florida; and TlOl through Hybritech, Inc., San Diego, California. 
antigens have been described (Table 1).4-16 For a 
more detailed description of these antibodies see refer- 
ence 17. Where applicable, the nomenclature and clus- 
ters of differentiation (CD) defined by the Second 
International Workshop on Human Leukocyte 
Differentiation Antigens are shown. 18* lg 
T Lymphocytes 
T lymphocytes were initially identified by their ability 
to spontaneously bind sheep erythrocytes (E rosette). 
T lymphocytes also react with T cell-specific antisera 
and T cell monoclonal antibodies which may also be 
used to identify T lymphocytes, and have proven to 
be more sensitive and discriminatory (Table 2).20-31 
Many of these antibodies react with immature T cells; 
others react with more mature T cells. Some of these 
antibodies identify antigens found on all T cells, 
whereas others occur only on T cell subsets. 
A summary of the more frequently referenced anti- 
bodies useful for the classification of lymphoma and 
lymphoid leukemia, and their cluster designations is 
shown in Table 3. 
Table 3 Frequently Referenced Antibodies with Cluster 
Designations 
Cluster Designation Antibody 
CD1 0KT6, anti-Leu-6, NAl/34 
CD2 OKTll, anti-T1 1, anti-Leu-5,9.6 
CD3 OKT3, anti-T3, anti-Leu-4, UCHT-1 
CD4 0KT4, anti-T4, anti-Leu-3 
CD5 OKTl, anti-Tl, anti-Leu-1, 10.2, TlOl 
CD7 anti-Leu-9, 3A1, WTI, 4A 
CD8 OKTS, OKT8, anti-T& anti-Leu-2 
CD10 anti-J5, BA-3, antiCALLA 
CD19 anti-B4 
CD20 anti-B 1 
CD21 anti-B2 
CD24 BA-I 
CD25 anti-Tat 
Immunoglobulin and T Cell Receptor Genes 
Recombinant DNA technology has provided impor- 
tant insights into antibody diversity and antigen- 
specific T cell receptors. 32 Immunoglobulins are com- 
posed of heavy and kappa and lambda light chains, 
encoded by genes on chromosome 14,2 or 22, respec- 
tively. 3 J-3 6 Immunoglobulin genes are encoded bv 
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discontinuous segments of DNA.37338 At one point in 
development, a potential antibody-producing cell 
must productively rearrange variable, diversity and 
joining genes (VDJ) which are then linked to the con- 
stant region locus. Immunoglobulin gene rearrange- 
ments are hierarchal; p heavy chain rearrangements 
precede light chain rearrangements; kappa light chain 
rearrangement precedes lambda light chains re- 
arrangement.38 These rearrangements can be detected 
by Southern blot analyses of DNA from B-cells using 
appropriately radiolabeled heavy or light chain 
probes. Heavy chain rearrangements have been identi- 
fied in non-B cells; light chain rearrangements appear 
to be restricted to B-cells. 3*, 39 Clonal rearrangements 
of light chain genes are therefore an extremely sensi- 
tive tool to identify B-cell malignancies. 
The antigen-specific T-cell receptor is a heterodimer 
formed by a 40-50 kilodalton (kd) a subunit (Tcr), and 
a 40-45 kd fl subunit (Tfl).40 It is associated with three 
20-25 kd peptide chains identified by the T3 monoclo- 
nal antibody.40 Recently, cDNA clones to the Tfl and 
Ta receptors have been isolated.41-43 The human TP 
receptor gene has been localised to chromosome 744 
and the human Ta receptor gene to chromosome 14.45 
TP gene rearrangements have been detected in 
malignant human T-cells by Southern blotting.46-48 
This technique can detect as few as 1% tumour cells in 
a mixed cell population; 46 it is a sensitive diagnostic 
marker for T-cell diseases. Interestingly, rearrange- 
ments of the T/I antigen receptor are reported in 25% 
of patients with non-T ALL,49 and in a small portion 
of leukemic B cellsso This is similar to the rearrange- 
ment of immunoglobulin heavy chain genes in 
approximately 10% of the leukemic T cell population 
studied.39 
Classification of the Lymphoid Leukemias and 
Lymphomas 
Acute Lymphoblastic Leukemia 
Acute lymphoblastic leukemia (ALL) is hetero- 
geneous. The first surface markers used to differen- 
tiate subclasses of ALL were E rosettes,5’*52 which 
identify a T cell subclass (15-20% of cases) and SmIg 
which identifies a B cell subset (< 5% of cases). Both 
T and B cell subgroups have an unfavourable progno- 
sis.53, 54 The next important advance in identifying 
ALL was development of an antiserum to the 
common ALL antigen (CALLA).SS CALLA or 
CD10 reactivity identified a non-B, non-T subclass of 
ALL patients (approximately 70% of cases) with a 
more favourable prognosis than T-ALL, B-ALL, or 
non-B, non-T ALL without CD10.54 Other markers 
such as Ia antigen were commonly found on non-T- 
ALL and could help differentiate non-T from T- 
ALL.56 By testing for cytoplasmic ~1 heavy chain, a 
subset designated pre-B ALL has been identified.57 
Except for the presence of cytoplasmic p, this subset 
expresses the same surface markers as the CDlO- 
positive form of non-T-ALL; it appears, however, to 
have a less favourable prognosis.58 
With the development of monoclonal antibodies, it 
became evident that the T cell subset of ALL was 
heterogeneous. 59-6 l More recently, studies of 
immunoglobulin gene rearrangements and monoclo- 
nal antibodies that identify B cell-associated antigens 
have demonstrated that most cases of non-T-ALL de- 
rive from the B cell lineage.62*63 We review these data 
and present a new classification for ALL based on 
these recent observations. 
Non-T-Acute Lymphoblastic Leukemia 
Two important areas of research have prompted a 
reassessment of non-T-acute lymphoblastic leu- 
kemia (non-T-ALL). First, monoclonal antibodies 
that recognise B cell-associated antigens have been 
identified; many are present on non-T-ALL cells. The 
most specific of these antibodies is probably anti-B4 
which reacts with 95% of cases of non-T-ALL.“*63 
Second, clonal rearrangements of immunoglobulin 
genes provide strong evidence for the B cell lineage of 
most cases of non-T-ALL.62,63 
Although Ia antigen is present on most non-T- 
ALL, and CD10 is present on 75% of cases of 
non-T-ALL, these antigens are also identified on 
approximately 10% of cases of T-ALL. Therefore, B 
cell-associated antigens (Table 1), which are not iden- 
tified on T-ALL cells, are the most useful in dis- 
tinguishing non-T-ALL. The CD20 and CD19 
antigens are model antigens for this discussion. 
Less than 5% of cases of ALL express SmIg 
(usually IgM); these cells are typically classified as 
B-ALL. These cells generally express other B cell 
antigens, including CD20, CD19, and Ia. 
B-ALL in children is probably a leukemic phase of 
non-Hodgkin’s or Burkitt’s lymphoma.52~53 Another 
marker that identifies a subset of non-T-ALL is cyto- 
plasmic p (Cp) heavy chain; K and I light chains, and 
SmIg, are typically absent.57 These cells are con- 
sidered pre-B cells. As indicated, most cases of non-T- 
ALL involve pre-B cells; thus Cc1 is useful in determin- 
ing the level of differentiation of pre-B cells. Pre-B 
cells that synthesise p heavy chain are the most mature 
cells of this group. 
Nadler and co-workers63 recently classified 138 
patients with non-T-ALL on the basis of monoclonal 
antibodies and immunoglobulin gene rearrangements. 
They divided these cases into four major subgroups, 
The first subgroup was Ia antigen-positive, represent- 
ing 5% of cases. Another subgroup expressed the Ia 
and B4 antigens representing 15% of cases. The third 
subgroup expressed the Ia, CD 19, and CD 10 antigens, 
comprising one third of the cases. Finally, one half of 
the cases of non-T-ALL were Ia, CD19, CDlO, and 
CD20 positive. The fourth group was further 
subdivided into cases with and without Cp. We 
propose that cases with Cp be placed in a separate 
group (group V) assuming that they are more mature. 
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Table 4 Classification of non-T-ALL 
Ia 
Antigens 
CD19 CD10 CD20 Cytoplasmic p 
Surface Membrane 
Immunoglobulin 
Group I 
Group II 
Group III 
Group IV 
Group V 
Group VI 
+ _ _ - - _ 
+ + _ - - _ 
+ + + _ - _ 
+ + + + - _ 
+ + + + + _ 
+ + +I- + - + 
Table 5 Classification of T-ALL 
Antigens 
CD7 CD5 CD2 CD3 CD4 CD8 CD1 
Group I 
Group II 
Group III 
+ + (90%) + (75%) - _ - - 
+ + + + (25%) + (90%) + (90%) + 
+ + + + +/-t +/-t _ 
* Found on virtually all T-ALL cells. 
t No longer simultaneous expression of T4/Leu-3 and T8/Leu-2 as found in Group II. 
The final and most differentiated group, group VI, 
represents SmIg-positive B-ALL (Table 4). 
T-Acute Lymphoblastic Leukemia 
T-acute lymphoblastic leukemic (T-ALL) repre- 
sents 15% to 25% of cases of ALL. Clinical features 
associated with T-ALL include a high blast cell count, 
predominance of male patients, older patients (15-20 
years), and mediastinal masses. T-ALL was originally 
identified by E rosette formation. The most sensitive 
marker for T-ALL is probably the CD7 pan-T 40 
kilodalton (kd) antigen. This antigen is present on 
most thymocytes and T cells but not on non-T-ALL 
or B cell lymphomas or leukemias.27-29 In a study of 
23 patients with T-ALL, all cases expressed CD7.28 
Interestingly, CD7 reacts with a small proportion of 
cases that appear to be myeloid leukemias.64 In 
addition, an unusually high incidence of CDlO, Ia, 
and CD24 expression has been reported in adults with 
T-ALL.65 Recently, rearrangement of the T/3 receptor 
gene in cases of T-ALL has been reported.46-50 
Further subclassification of T-ALL is controversial. 
Reinherz and colleagues proposed a subclassification 
for T-ALL according to the level of thymic differen- 
tiation.sg Several elements of their subclassification of 
T-ALL have been confirmed; others are controversial. 
The most primitive thymocytes, referred to as early or 
stage I thymocytes, react with T9 and TIO antibodies 
and account for approximately 10% of the thymic 
cells. In their study, Reinherz and co-workers 
reported that most T-ALL cells express antigens 
found on early thymocytes. The next level of thymic 
differentiation, which included the majority of thymo- 
cytes, is referred to as common or stage II. These cells 
lose T9, retain TlO, and acquire CDl, CD4, and CD8 
antigens. Approximately 20% of cases of T-ALL 
express this phenotype. Mature stage III thymocytes 
no longer express CD1 but segregate into CD4 or 
CD8 subsets similar to peripheral blood T 
lymphocytes. Only rarely did Reinherz, et al find T- 
ALL cells with the phenotype of mature thymocytes 
or circulating T lymphocytes. In a more recent study, 
Roper and co-worker@* confirmed many of the 
findings reported by Reinherz, but reported some 
major differences. In this study, only one third of the 
T-ALL patients had the phenotype of early or stage I 
thymocytes; most had the phenotype of either 
intermediate or late stage thymocytes. In Table 5 we 
summarize these data and propose a scheme for the 
classification of T-ALL. The common marker for all 
of the subgroups is CD7. Nearly all cells also express 
CD5 and most express CD2 that identifies the E- 
rosette receptor. 
Although Roper and co-worker@’ studied clinical 
correlations between these three groups of T-ALL, 
they found no unique clinical features among the sub- 
groups and no differences in remission duration or 
survival. However, the groups were too small for sta- 
tistically valid conclusions. Presently we believe it use- 
ful to subclassify T-ALL using this system so that 
data from a number of institutions can be analysed for 
clinical correlations between the subgroups of T-ALL. 
Non-Hodgkin’s Lymphoma 
The non-Hodgkin’s lymphomas are a diverse group of 
neoplasms whose pathologic classification are contro- 
versial. It is even more difficult to correlate pathologic 
classification with immunologic classification. There 
are, however, a number of immunologic patterns that 
emerge, and we will attempt to place them within the 
non-Hodgkin’s lymphoma working classification6’j as 
well as the Rappaport classification.67 
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Follicular or Nodular Lymphomas 
The follicular or nodular lymphomas most likely 
represent neoplastic proliferation of lymph node- 
derived follicular center B lymphocytes. The cell type 
may be a small cleaved cell (nodular lymphocytic 
poorly differentiated lymphoma by the Rappaport 
classification), mixed small cleaved and cleaved or 
non-cleaved large cell (nodular mixed), or predomi- 
nantly large cell (nodular histiocytic). The first two 
cell types fall within the working classification as low- 
grade lymphoma, whereas the latter cell type as an 
intermediate grade lymphoma. While the predomi- 
nantly small cleaved cell will almost always express 
high density monoclonal SmIg, larger cells may be 
SmIg negative. 68.69 However, the small cleaved and 
large cells will routinely express Ia, CD19, and CD20 
antigens and will often express the CD21 antigen.69 
Interestingly, more than half of these cases will also 
express CD 1 0,69, 7 O Follicular lymphoma cells may be 
found in the patient’s peripheral blood as a ‘leukemic’ 
phase of the disease (formerly referred to as lympho- 
sarcoma cell leukemia). These cells can usually be 
differentiated from chronic lymphocytic leukemia 
(CLL) cells as they may express CDlO, which is not 
expressed on CLL cells; they do not express the CD5 
pan-T antigen found on CLL cells; and they generally 
will have a low percentage of mouse erythrocyte 
rosette formation (see belo~).‘~~~~ 
Malignant Lymphoma, Small Lymphocytic 
Malignant lymphoma, small lymphocytic (diffuse 
lymphocytic well-differentiated lymphoma in the 
Rappaport classification) is a low-grade malignancy 
and some cases may be identical to CLL. Also, in- 
cluded within this subclassification are the plasmacy- 
toid lymphocytic subgroups with and without an IgM 
monoclonal gammopathy; some of these cases are 
similar to Waldenstrom’s macroglobulinemia (de- 
scribed below). Surface markers on these small lym- 
phocytic cells include low intensity SmIg, mouse 
erythrocyte receptors, C’3 and receptors for the Fc 
portion of IgG and la, CD19, CD20, CD21, CD24, 
and other B cell antigens. These features are similar to 
CLL and the cells also express the CD5 pan-T antigen. 
Malignant Lymphoma, D@use Small Cleaved Cell and 
Difuse Mixed Small and Large Cell 
Malignant lymphoma, diffuse small cleaved cell (dif- 
fuse lymphocytic poorly differentiated lymphoma in 
the Rappaport classification) is an intermediate prog- 
nostic group. The cells are B lymphocytes that (similar 
to follicular lymphoma cells) usually display large 
amounts of monoclonal SmIg. Unlike follicular lym- 
phoma cells, however, they do not usually express 
CDlO.‘O Similar to follicular lymphoma cells, they 
do not express the CD5 antigen as do cells from 
most small lymphocytic lymphomas and CLL. How- 
ever, all of these cell types have in common the expres- 
sion of Ia, CD19, CD20, CD21, and other B cell 
antigens. 69 
The diffuse mixed small and large cell (diffuse mixed 
lymphocytic-histiocytic) lymphomas have not been 
extensively studied but are most likely predominantly 
B cell diseases. They are also considered an inter- 
mediate grade prognostic group. 
Malignant Lymphoma, Difuse Large Cell and Large 
Cell Immunoblastic 
In the working classification, the diffuse large cell lym- 
phomas are considered within the intermediate prog- 
nostic group, whereas large cell immunoblastic 
lymphoma is a high-grade malignancy. By the Rappa- 
port classification, both of these cell types would be 
described as histiocytic. This is clearly a misdesigna- 
tion since 80-90% of cases represent clonal expan- 
sions of malignant B cells.73 A high percentage of 
these cells express T9 and TlO antigens.6s Fifty-seven 
cases of diffuse large cell lymphoma were recently 
studied and divided into the following subgroups: (1) 
CD20, CD19, and SmIg positive; CD21 negative 
(50%), (2) CD20, CD19, SmIg, and CD21 positive 
(30%), (3) CD20 and CD19 positive; SmIg and CD21 
negative (lo%), and (4) CD20 and SmIg positive, and 
CD21 negative (1Ooh).74 These data suggest that most 
of these lymphomas’s represent the malignant 
counterpart of B cells at the mid-stage of 
differentiation. Ten to 20% of cases are T cell lineage; 
2% are derived from the monocyte-myeloid lineage. 
Recently, clonal rearrangement of the T/I receptor has 
been described in patients with T-derived non- 
Hodgkin’s lymphoma.47*4* 
Malignant Lymphoma, Lymphoblastic 
Malignant lymphoma, lymphoblastic or lymphoblas- 
tic lymphoma is a high-grade malignancy. The nuclear 
membrane is characteristically deeply subdivided 
imparting either a lobulated (convoluted) appearance 
or a fine linear (nonconvulated) subdivision in a 
round nucleus. Lymphoblastic lymphoma represents 
approximately one-third of the cases of non- 
Hodgkin’s lymphomas in children and 5% of cases in 
adults. The disease is more prevalent in males; these 
patients often have a mediastinal mass. In some cases, 
the disease may evolve into a leukemic phase morpho- 
logically indistinguishable from T-ALL. The malig- 
nant cells are T cells, form E rosettes, react with T cell 
antisera,7 5-77 and have rearrangements of the Tfi 
receptor. ‘* Studies with monoclonal antibodies have 
demonstrated marked heterogeneity. Lymphoblastic 
lymphoma cells differ from T-ALL in that the cells 
rarely express the surface markers common to imma- 
ture thymocytes (group I);79 phenotypes are equally 
divided among group II and group III T-ALL. Inter- 
estingly in 40% of cases, the cells are reported to ex- 
press CD 10; CD10 expression is less common in 
T-ALL ( 1O%).7’J 
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Malignant Lymphoma, Small Noncleaved Cell 
This category includes Burkitt’s lymphoma and other 
lymphomas previously designated undifferentiated 
non-Burkitt type (high grade). Burkitt cells from peri- 
pheral blood and bone marrow are usually classified 
as L3 by the French-American-British (FAB) cri- 
teria.,80 Most cases of Burkitts lymphoma from 
Africa are associated with the Epstein-Barr virus 
(EBV); these are endemic. Most non-African cases 
(non-endemic) are EBV negative.s* Chromosomal ab- 
normalities involving chromosome 8 (carrying the 
oncogene c-myc) and either 2, 14, or 22 occur in vir- 
tually all cases of endemic and non-endemic Burkitt’s 
lymphoma.*2 These are designated t(2;8), t(8;14) and 
t&22), respectively. Usually the light chain class 
expressed on these cells is correlated with the trans- 
location, i.e., K in t(2;8) and I in t(8;22). African 
Burkitt’s lymphoma cells have C’3 and receptors for 
the Fc portion of IgG in addition to the EBV receptor. 
American Burkitt’s lymphoma cells do not.*l Pheno- 
typing of cell lines derived from patients with un- 
differentiated lymphoma of the Burkitt’s and non- 
Burkitt’s type have demonstrated heterogeneity.83 
These studies suggest that Burkitt cells follow a diver- 
gent pathway of B cell evolution as they are all TdT 
negative (unlike early B cell non-T ALL). The most 
primitive of the Burkitt cell lines are Ia and CD20 posi- 
tive and may or may not express CALLA. Maturation 
was evident in other Burkitt cell lines by the expres- 
sion of CCL, surface membrane IgM, and/or IgM secre- 
tion. Some of these Burkitt cell lines also expressed the 
Tat antigen. 
Peripheral T Cell Lymphoma 
Peripheral T cell lymphoma would usually be classi- 
fied as malignant lymphoma, large cell immunoblastic 
(high grade) under the working formulation. How- 
ever, this tumour has unique features and will be de- 
scribed separately. The term ‘peripheral T cell 
lymphoma’ is used to distinguish it from lymphoblas- 
tic lymphoma of presumed thymic origin. Peripheral 
T cell lymphomas are thought to derive from peri- 
pheral T lymphocytes in lymph nodes and other, non- 
lymphoid sites. These lymphomas comprise a broad 
spectrum of morphologic types of lymphocytes. In all 
instances the cells have T cell markers admixed with 
epithelioid histiocytes, plasma cells, eosinophils, and 
vascular hypertrophy. Clinically, peripheral T cell 
lymphoma is characterized by generalized lympha- 
denopathy, weight loss, and a high incidence of pul- 
monary involvement.84 Surface markers are usually 
but not always characteristic of mature T helper 
cells,85 including CD4 helper-associated antigen CD3, 
CD2, and CD5 pan-T antigens. Rearrangement of the 
T/3 receptor has been reported.78 
Ty Lymphoprollyerative Disease 
Ty lymphocytes are a subset of T lymphocytes with 
receptors for the Fc portion of IgG. A high propor- 
tion of normal Ty lymphocytes are large granular lym- 
phocytes. These cells are thought to be responsible for 
natural killer (NK) and antibody-dependent cell- 
mediated cytotoxicity. A lymphoproliferative dis- 
order made up of predominantly Ty lymphocytes has 
been described; we refer to this as chronic Ty lympho- 
proliferative disease .86 Typically, patients are elderly, 
males, with increased Ty lymphocytes infiltrating the 
bone marrow and spleen. 86,87 Although the disease is 
not rapidly progressive, neutropenia and recurrent 
infections are common. Most patients do not require 
chemotherapy. Variants of this disease, including a 
more aggressive form have also been described.88 
Clonal chromosomal abnormalities,s9 as well as clo- 
nal rearrangement of the T/I receptor have been 
reported. 57,90 Cells from chronic Ty lymphoprolifera- 
tive disease usually contain acid phosphatase and /?- 
glucuronidase and express the pan-T antigens 
CD3, CD2, the suppressor-associated antigens CD8, 
and the NK-associated antigens Leu-7 (HNK-1). 
Cutaneous T Cell Lymphoma (Mycosis Fungoides, 
SPzary Cell Leukemia) 
Skin lesions are the most prominent feature of 
patients with cutaneous T cell lymphoma.91 Lesions 
vary from limited plaques to diffuse plaques, tumours, 
and generalised erythroderma. Rare patients with 
limited plaque disease and less than 50% with general- 
ised plaques and tumours have extracutaneous disease 
detected by light microscopy evaluation of peripheral 
blood and lymph nodes. Special studies including 
cytogenetic analysis and electron microscopy indicate 
blood involvement in over half of the patients with 
limited plaque disease and most patients with general- 
ized plaques and skin tumours.92 Analysis of the T/I 
receptor rearrangement will likely reveal a higher pro- 
portion of cases with blood involvement. 
The malignant cells in this disorder are character- 
ised by a cerebriform nucleus. In the skin, the cells are 
referred to as mycosis fungoides cells and in the peri- 
pheral blood as Stzary cells. Sezary and mycosis cells 
form E rosettes, react with T antisera and anti-T 
monoclonal antibodies,93 and have clonal rearrange- 
ments of the T/I receptors.549 55* 85994 In most cases, 
the cells express the phenotype associated with normal 
helper/inducer T lymphocytes (CD5, CD3, CD4)95 
and function as helper T lymphocytes in in vitro 
assays.96 
Adult T Cell LeukemialLymphoma 
Adult T cell leukemia/lymphoma is associated with a 
human retrovirus designated human T cell leukemia/ 
lymphoma virus-l (HTLV-I).“’ Virtually all patients 
tested have antibodies to HTLV-1.9* Patients with 
this disease have been identified primarily in Japan, 
the USA and the Caribbean. In the USA the patients 
are young (median age 33 years) predominantly black, 
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and born in the Southeastgs Common clinical 
features include a rapid onset of symptoms with 
rapidly progressive cutaneous lesions and hypercal- 
cemia. Skin lesions are variable and include small and 
large discrete or confluent nodules, or nonspecific 
plaques, papules or patches. Patients have increased 
bony turnover with abnormal bone scans, elevated 
alkaline phosphatase and may have lytic bone 
lesions.gg Lymphocytosis is common, and circulating 
malignant cells are present in low numbers in most 
patients. Peripheral lymphadenopathy is common 
with retroperitoneal and hilar involvement in approxi- 
mately 50% of cases. Bone marrow, gastrointestinal, 
pulmonary, leptomeningeal and hepatic involvement 
are somewhat less common (2&50%). Response to 
combination chemotherapy is prompt and often com- 
plete, but duration of response is short (median 13 
months). Opportunistic infections are extremely 
common in these patients. 
The typical malignant circulating cells have moder- 
ately condensed nuclear chromatin, inconspicuous 
nucleoli, and a markedly irregular nuclear contour in 
which the nucleus is divided into several lobes.100 
These cells typically express the phenotype of helper/ 
inducer Ty lymphocytes,101 and CD25 that identifies 
the IL-2 receptor. lo2 Variability in the expression of 
CD2 and CD3 have been reported.‘Ol Clonal 
rearrangements of the Tfl receptor are identified in 
cells from patients with adult T cell 
leukemia/lymphoma.48* 50, 78, *’ The leukemic cells 
are reported to suppress B cells Ig secretion,lo3 by a 
complex mechanism involving induction of sup- 
pressor cells following activation of normal suppres- 
sor cell precursors. 1 O 1 
Chronic Lymphocytic Leukemia and Prolympho- 
cytic Leukemia 
Chronic lymphocytic leukemia (CLL) is a monoclonal 
proliferation of SmIg-positive B lymphocytes. lo4* lo5 
Clonality of CLL has been demonstrated by expres- 
sion of a single Ig light chain, either K or 2, on the cell 
surface membrane. 1 O6 More sophisticated techniques 
have confirmed clonality by showing unique immuno- 
globulin idiotype specificities,107 a single pattern of 
glucose-6-phosphate dehydrogenase activity, * O8 
clonal chromosome abnormalities,10g or immuno- 
globulin gene rearrangement.47 The malignant B cell 
involved in CLL is an intermediately differentiated 
cell. The cell appears frozen in differentiation and 
does not mature to the final stage of B cell develop- 
ment, the mature plasma cell. However, recent data 
have demonstrated that in vitro treatment of these 
cells with phorbol esters or pokeweed mitogen can in- 
duce differentiation into mature immunoglobulin- 
secreting plasma cells. 1 lo Under certain circum- 
stances, CLL cells stimulated in vitro with phorbol 
esters differentiate into cells with cytoplasmic protru- 
sions and other characteristics of hairy cell leu- 
kemia. l l 1 
The B lymphocyte characteristic of CLL displays a 
relatively small amount of SmIg and this has been 
used to distinguish CLL from the leukemic phase of 
nodular and diffuse lymphocytic lymphomas and 
from prolymphocytic leukemia where the cells gener- 
ally display considerably more SmIg. 1 1 2 Immunog!o- 
bulin isotype analyses indicates that most CLL 
display a single heavy chain class; typically, p or p and 
6. Less commonly, y, a, or no heavy chain determi- 
nant is found. CLL cells display either K or 1 light 
chains but never both. B-CLL cells display receptors 
for mouse erythrocytes, a feature characteristic of 
immature B lymphocytes. 1 l3 The cells also have the 
receptor for the Fc portion of IgG and complement 
with a relative increase of C’3d receptors (CR2) over 
C’3b receptors (CRl); this is typical of immature B 
cells. 1 l4 B-CLL cells display several antigens, includ- 
ing Ia and human B cell antigens such as CD19, 
CD20, CD21 and CD24. One unanticipated finding 
was that B CLL cells display the CD5 antigen 
previously thought to be restricted to T lymphocytes. 
CD5 on CLL cells was first recognised by using 
heteroantisera115 and later with the TlOl and 
equivalent monoclonal antibodies.32 The precise 
meaning of this anomalous expression of a T cell 
antigen is unclear; although a normal B cell 
counterpart has been reported in human tonsil lymph 
nodes,’ 1 6 and stimulation in vitro of normal B cells 
with phorbol ester may induce expression of this 
antigen.’ 1 7 Recently, the TQl antigen, reported to 
define the inducer of suppression within the T helper 
subset, was identified on 60 of 75 B-cell patients’ 
cells. 1 1 * 
Rearrangement of immunoglobulin heavy and light 
chains have been reported as expected in B-CLL cells, 
however, rearrangement of the T/I receptor has also 
been reported in approximately 10% of cases of 
B-CLL.So This is analogous to the reported Tfi re- 
arrangement in non-T (pre-B) ALL, and again em- 
phasises that immunoglobulin and Tfi receptor 
rearrangement alone are not adequate to assign 
lineage. 
In 3% to 10% of patients with CLL, the disease 
may evolve into a diffuse histiocytic lymphoma 
(Richter’s syndrome). This may be associated with 
loss of the TQl antigen, 1 1 * Most data suggest that 
this evolution involves transformed follicular center B 
cells rather than histiocytes or macrophages. Some 
transformations represent evolution of the malignant 
clone with expression of the same monoclonal 
immunoglobulin and karyotypic abnormality present 
in the original CLL clone. * 1 g In other cases, the lym- 
phoma cells have different markers and immuno- 
globulin gene rearrangements than the original CLL 
cells; these cases probably represent the concomitant 
development of a B cell lymphoma or a histiocytic 
malignancy in patients with CLL. ’ 20* ’ 21 
Prolymphocytic leukemia (PL) is related to CLL 
and is also likely to be derived from cells from the 
medullary cords of the lymph node. Immunoglobulin 
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gene rearrangements of heavy and light chains have 
been reported.lz2 Patients with PL generally have ex- 
tremely high blast counts and splenomegaly but lack 
significant lymphadenopathy. Prolymphoblasts are 
likely activated cells and appear morphologically 
immature with a fine lacy nuclear chromatin and one 
to two nucleoli; they may contain intracytoplasmic 
granules. These cells generally have higher density 
SmIg than CLL cells; they have Ia and CD19 antigens 
and may form rosettes with mouse erythrocytes.72 PL 
cells from 14 consecutive patients reacted with the 
FMC7 monoclonal antibody that recognises an anti- 
gen found on one-half of normal B lymphocytes, 
while cells from only five of 20 patients with CLL 
reacted with this antibody.7 
Approximately 5% of cases of CLL and PL result 
in a malignant proliferation of T rather than B cells. 
These cells react with T antisera and anti-T mono- 
clonal antibodies reflecting the phenotypes of mature 
T lymphocytes; they lack SmIg and other B cell 
markers.‘23*‘24 Many of these patients have diffuse 
organ and skin involvement. l* 3 
Hairy Cell Leukemia 
Hairy cell leukemia (leukemic reticuloendotheliosis) is 
characterised by invasion of the bone marrow and 
spleen by morphologically distinct mononuclear cells 
with ‘hairy’ cytoplasmic projections. l 2 5 These cells 
usually contain an isoenzyme of acid phosphatase 
(isoenzyme 5) that is resistant to tartrate; this iso- 
enzyme is not unique to hairy cells. Surface markers of 
hairy cells are most consistent with a monoclonal pro- 
liferation of B lymphocytes.126 SmIg with a single 
light chain is frequently identified,126 as are B cell- 
associated antigens. Interestingly, the PCA-1 antigen 
(but not the PC- 1 antigen) typically on plasma cells, is 
identified on hairy cells; these data suggest that hairy 
cells may be pre-plasma cells.127 Perhaps the most 
convincing evidence for the B cell origin of hairy cells 
comes from studies of immunoglobulin genes which 
indicate clonal rearrangement of heavy chain genes 
and at least one light chain.‘*** ‘*’ Most cases of hairy 
cell leukemia demonstrate CD25 typically identified 
on select T cell malignancies and activated T cells.*2g 
Myeloma and Related Disorders 
The malignant B cells of Waldenstrom’s macroglobu- 
linemia, heavy chain disease, and multiple myeloma 
represent a further step in the maturation of medul- 
lary cord B cells.‘04 Like CLL cells, cells from 
patients with Waldenstrom’s macroglobulinemia ex- 
press SmIg and Ia, CD20, and CD19 antigens. l l 
Unlike CLL cells, however, these cells express the 
PCA-1 antigen and do not express the CD21 antigen 
nor rosette with mouse erythrocytes.72 The plasma 
cell and its malignant counterpart, the myeloma cell, 
represent the most differentiated B lymphocytes. 
These cells synthesise large quantities of 
immunoglobulin and have CIg, but usually lack SmIg 
and the Ia, CD20, CD21, and CD19 antigens.130 
Plasma cells and myeloma cells, like other mature B 
lymphocytes, usually lack CDlO, but a recent study 
has suggested that rare cases of CDlO-positive 
myeloma represent an aggressive subtype with a poor 
prognosis. l 3 l Interestingly, plasma cells and myeloma 
cells stain intensely with the OKTlO monoclonal 
antibody as well as the anti-PCA-1 and anti-PC-l 
antibodies.13*q 133 
Conclusion 
The exciting advances in molecular biology and the 
hybridoma technology over the past 10 years have led 
to major advances in our understanding of the cellular 
origin of lymphoma and leukemia and will likely lead 
to a better understanding of the etiology of these dis- 
eases. Utilising these techniques it is now possible to 
more accurately diagnose and classify these disorders; 
these data may also have therapeutic implications. It 
is also possible to use molecular probes to detect mini- 
mal residual disease. In the future, monoclonal anti- 
bodies conjugated to isotopes, drugs, and/or toxins 
will likely have a role in the therapy of certain leu- 
kemias and lymphomas. We look forward to this 
exciting new era in cancer therapy and diagnosis. 
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